ANDHealth’s flagship commercialisation program has recorded its highest level of demand to date, with more than 90 digital and connected health companies applying for its latest intake.
Applications for the previous ANDHealth+ round were 65 per cent higher than the average across the preceding four rounds, with five companies ultimately selected for the 18-month program.
ANDHealth has now opened applications for its next round, with up to five companies able to access a share of $5 million in non-dilutive funding alongside commercialisation support.
ANDHealth+ is supported by the Australian Government through the Medical Research Future Fund’s Medical Research Commercialisation Initiative and does not take equity in participating companies.
The program is aimed at companies at proof-of-concept stage or later, providing support across areas including clinical and economic evidence, regulatory and reimbursement strategy, enterprise sales readiness, data and technical validation and international market entry.
ANDHealth chief executive Bronwyn Le Grice said the record demand reflected both the strength of Australia’s digital and connected health pipeline and the challenges companies faced accessing capital.
“The response is a powerful signal of the depth of digital and connected health innovation being developed across the country, but it also reflects the reality that access to capital remains one of the greatest barriers facing companies seeking to translate evidence-based technologies into sustainable, scalable businesses,” Ms Le Grice said.
“ANDHealth+ exists to help high-potential companies build the clinical, commercial and technical evidence, partnerships and market pathways they need to become fit for investment and fit for deployment.”
Five companies were selected from the previous round to join ANDHealth+ earlier this year: Australis Scientific, Corcillum, Earflo, Kraken Coding and MoreGoodDays.
Ms Le Grice said software-enabled and software-based health technologies faced different commercialisation pathways from traditional biopharmaceuticals and medical devices.
“These companies need specialist support from people who understand the health system, the evidence expectations of customers and investors, and what it takes to turn a promising technology into a product or service that can be adopted at scale,” she said.
“Our role is to help Australian companies grow locally and scale globally, creating high-value jobs, attracting investment and delivering technologies that make health and care more accessible, effective and sustainable.”
ANDHealth said the 28 companies that have completed ANDHealth+ to date have collectively raised more than $211 million in follow-on funding, generated more than $97 million in new revenue and created 558 jobs, with their technologies reaching more than 4.7 million patients.
It said 93 per cent of alumni companies had raised follow-on funding, while every dollar invested by government through the program had returned nearly $20 in new capital.
The opening of the latest round follows ANDHealth+ being named a finalist in the 2026 Prix Galien USA Awards’ Best Incubators, Accelerators and Equity category.
ANDHealth said it was the first Australian commercialisation organisation and the only organisation from the Asia-Pacific region nominated in the category. It is one of 11 organisations shortlisted, alongside institutions including the Mayo Clinic, with the winners due to be announced on 29 October.
Applications for the latest ANDHealth+ round close on 28 September 2026.
Add Comment